Serum Thrombopoietin Levels and Its Relationship With Thrombocytopenia in Patients With Cirrhosis

Tuncer Temel 1; Dondu Uskudar Cansu 2; Halide Edip Temel 3; Aysegul Harmanci Ozak yol 1

1Department of Internal Medicine, Division of Gastroenterology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey
2Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey
3Biochemistry Department, Pharmacy Faculty, Anadolu University, Eskişehir, Turkey

Corresponding Author: Tuncer Temel, Department of Internal Medicine, Division of Gastroenterology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Turkey. Tel: +90-2222929579, Fax: +90-222293772, E-mail: tttemel@ogu.edu.tr

Received: February 25, 2014; Revised: March 22, 2014; Accepted: April 13, 2014

Background: Patients with cirrhosis usually have thrombocytopenia in discrete levels. The mechanism of thrombocytopenia is thought as splenic sequestration and destruction of platelets, impaired bone marrow generation and diminished hepatic thrombopoietin synthesis.

Objectives: The aim of this study was to evaluate serum thrombopoietin levels and its relationship with thrombocytopenia at patients with cirrhosis.

Patients and Methods: Ninety-two cirrhotic patients and 45 healthy controls without history or findings of pathologies that can effect thrombopoietin levels were enrolled by simple random sampling to patient and control groups of this case control study performed at Eskişehir-Turkey. Thrombopoietin was measured in serum samples with a solid phase enzyme-linked immune absorbent assay. Additionally, spleen size and volume index were determined.

Results: Platelet counts were lower in patients with cirrhosis (97000 ± 8000/mm³) than in healthy subjects (240000 ± 51000/mm³, P < 0.001). Significant difference was determined for platelet counts among child A, B and C stages (Child A vs. Child B P < 0.05 Child A vs. Child C P < 0.001-Child B vs. Child C P < 0.05). Serum TPO concentration was higher (69 ± 12 pg/mL) in cirrhotic group than healthy controls (49 ± 9 pg/ml)[P < 0.05]. No significant difference in TPO levels were found among the Child A, B and C stages (64 ± 11 pg/mL, 75 ± 13 pg/mL and 68 ± 10 pg/mL, respectively). Spleen size and SVI was significantly higher in the cirrhotic patients than healthy controls (148 ± 14 mm vs. 98 ± 11 mm, P < 0.001-9167 ± 287 cm² vs. 418 ± 123 cm²). Significant difference was determined for spleen size and spleen index among child A, B and C stages (Child A vs. Child B P < 0.05 Child A vs. Child C P < 0.001-Child B vs. Child C P < 0.05). TPO levels were significantly different between cirrhotic patients with platelet levels below 50,000/mm³ (n = 76, plt-count: 41000 ± 8300/mm³, TPO levels: 73 ± 7 pg/mL) and above 50,000/mm³ (n = 16, plt-count: 105000 ± 9500/mm³, TPO levels: 65 ± 10 pg/mL) (P < 0.01). In correlation analysis, there was a strong negative correlation between platelet count-spleen size (P < 0.001, r = -0.74) and platelet count-serum TPO levels (P < 0.001, r = -0.71).

Conclusions: Our results suggest that liver cirrhosis does not cause impaired thrombopoietin production even in the late stage of disease. Thrombopoietin has no contribution for the occurrence of thrombocytopenia in cirrhosis; splenic sequestration seems to be the main factor.

Keywords: Liver Cirrhosis; Thrombocytopenia; Thrombopoietin

1. Background

Liver diseases have several effects on distribution, survival and production of hematopoietic elements (1). Thrombocytopenia; one of the fort coming haematological complication of liver cirrhosis; is often defined as a platelet count below 100000 mm³. Platelet levels beneath 50000 mm³ are referred as severe thrombocytopenia. Cirrhotic patients with or without cancers often require numerous medical and/or surgical procedures during diagnosis and therapy. The presence of thrombocytopenia can aggravate surgical or traumatic bleeding and can also significantly complicate routine patient care, such as liver biopsy, antiviral therapy and medically indicated or elective surgery for cirrhotic patients, resulting in delayed or cancelled medical management and affecting the administration of effective treatment for several conditions (2). The mechanism of thrombocytopenia is thought as splenic sequestration and destruction of platelets (3), impaired bone marrow generation and diminished hepatic thrombopoietin (TPO); principal regulator of megakaryo-thrombopoiesis; production (4). The main source of TPO is liver (5). TPO is the major physiological regulator of platelet production. Binding of TPO to its receptor which is expressed on the surface of stem cells, megakaryocyte progenitor cells, megakaryocytes and platelets activates janus kinase/signal transducers and activators of transcription (JAK/STAT) pathways and...
stimulates thrombopoiesis. TPO levels are correlated with platelet production. (4, 5). Data at the literature about TPO levels and its relation with thrombocytopenia for cirrhotic patients is conflicting. Although in most studies serum TPO levels are decreased in liver cirrhosis, thrombocytopenia is correlated positively with TPO levels and platelet counts are increased after recovery of liver synthesis function; orthotopic liver transplantation; some studies have been reported that serum TPO concentrations are elevated or normal in thrombocytopenic cirrhosis patients, no correlation was determined between TPO levels and thrombocytopenia, and rather than TPO levels, decreased platelet counts are associated with other factors like splenic sequestration (6-20).

2. Objectives
The aim of this study was to evaluate serum thrombopoietin levels and its relationship with thrombocytopenia in patients with cirrhosis.

3. Patients and Methods

3.1. Patients
Ninety-two cirrhotic patients among all cirrhotic patients who admitted to our clinic between 01.03.2005-01.02.2013 (mean age 58 ± 11 years, 42 females and 50 males) with or without thrombocytopenia and 45 healthy controls (23 females and 22 males, mean age 54 ± 10 years) were enrolled by simple random sampling to patient and control groups of this case control study performed at Eskisehir-Turkey. The number of patient and control groups were determined by two sample t-test power analysis with an expected power of 0.87. Eskisehir Osmangazi University local ethics committee approved the study (28.02.2005 ethics committee acceptance number: 9) and informed consents were obtained. Diagnosis of liver cirrhosis was made according to the clinical and laboratory parameters, while the diagnosis was confirmed by histological examination in 72 of the patients, diagnosis of cirrhosis was established by liver function tests (bilirubin, albumin, international normalized ratio), ultrasound findings (ascites and splenomegaly, dilated portal and splenic veins, presence of portal collaterals and irregular-nodular contours of the liver) at patients with contraindications to liver biopsy. Exclusion criteria were as follows: diagnosis of essential thrombocytopenia or history of familial essential thrombocytopenia, inherited or acquired bone marrow failure, previous or ongoing application of recombinant hematopoietic growth factors, autoimmune diseases rather than autoimmune hepatitis or history of immune suppressive treatment, diagnosis of a hematopoietic or solid malignancy, antiviral therapy application within last six months. The severity of liver cirrhosis was assessed according to the Child Pugh’s classification (21). The cause of liver cirrhosis was hepatitis B virus (HBV) infection in 22 cases, hepatitis C virus (HCV) infection in 38 cases, alcohol in four cases, autoimmune hepatitis in 10 cases and cryptogenic cirrhosis in 18 cases. Thirty of the patients were at Child A, 32 of the patients were at Child B and 30 of the patients were at Child C stage. Complete blood count, liver function tests including serum albumin levels and prothrombin time were determined at biochemistry and haematology laboratories of Eskisehir Osmangazi University, Medical Faculty. The size of the spleen was measured by ultrasound, and the spleen index was calculated by multiplication of the long and short axes. Characteristics of the patients are summarized at Table 1.

3.2. TPO Assay
Venous peripheral blood samples were collected and centrifuged at 2500 rpm for 10 minutes. The serum was separated and stored at -75°C. TPO levels were detected by ELISA (Quantikinine, RD Systems, Wiesbaden Nordenstand, Germany) at haematology laboratory.

3.3. Statistical Analysis
Statistical analysis was performed using a commercial statistical software package version 13.0 for Windows. Data are shown as the mean ± standard deviation (SD). Means between two groups were compared by using the one-way analysis of variance, (Tukey post-hoc test) used to evaluate the association between two variables. A value of P < 0.05 was accepted as statistically significant.

4. Results
Platelet counts were lower in patients with cirrhosis.

---

**Table 1. Characteristics of the Patients a,b**

| Age, y | Child A (n = 30) | Child B (n = 32) | Child C (n = 30) | Cirrhosis Patients (n = 92) |
|--------|-----------------|-----------------|-----------------|-----------------------------|
|        | 58 ± 10         | 58 ± 13         | 57 ± 9          | 58 ± 11                    |
| Sex, M/F | 17/13           | 15/17           | 14/16           | 46/46                      |
| Albumin, g/dL | 4.03 0.59       | 3.04 0.45       | 2.44 0.36       | 3.29 0.83                  |
| PT, sec | 15.0 1.45       | 17.49 2.16      | 21.12 2.60      | 17.4 3.10                  |
| Bilirubin, g/dL | 1.29 0.56       | 1.9 0.87        | 7.42 4.54       | 2.98 3.37                  |

a Data are presented as Mean ± SD.
b Abbreviation: PT, Prothrombin time.
Thrombocytopenia is generally considered secondary to the increased sequestration and pooling of platelets in enlarged spleen and destruction of platelets (23, 24). However, no exact correlation between the portal pressure and the platelet count has been determined. Moreover, thrombocytopenia may persist after splenectomy or portal decompression and return to normal platelet count was observed following liver transplantation (25).

As a result diminished thrombocyte production due to TPO; principal regulator of megakaryogenesis and thrombopoiesis, which is predominantly produced by the liver; insufficiency secondary to advanced liver failure is accused as the reason of thrombocytopenia in cirrhosis (26). While some of the studies determined low plasma levels of TPO (6, 11, 13, 15, 18), others evaluated normal or high plasma levels in contrast of decreased thrombocyte levels at cirrhotic patients (3, 9, 20, 26, 27). Bone marrow examinations of cirrhotic patients revealed absolutely normal findings (28, 29).

In our study, cirrhotic patients had higher TPO levels than healthy subjects and a statistically significant negative correlation was determined between platelet counts and serum TPO levels. Circulating TPO levels is regulated through its binding to the TPO receptor; which is mainly expressed on bone marrow megakaryocytes and circulating platelets; rather than the up-regulation or down-regulation of its production (4, 5). While TPO is produced constantly by the liver, kidney, and marrow stroma, its circulating levels depends on the total amount of TPO receptor (25). The observed increase in circulating TPO in our study might be explained by decreased consumption of TPO secondary to thrombocytopenia and contradictory data throughout the literature may be related with ignorance of the TPO receptors at bone marrow.

Proportion of reticulated platelets (RP) in total platelets (%RP) and glycosalcin index (GCI) are indicators of platelet turnover (30). The accelerated platelet turnover in cirrhotic patients indicates an accelerated platelet clearance in the periphery through hypersplenism. Spleen volume index was significantly elevated and platelet counts were significantly reduced in cirrhotic patients than the healthy controls in our study. A strong inverse correlation was observed between platelet count and spleen size in the patients.

The identification of megakaryocytes based on morphological studies at the light microscopy is difficult and results are therefore often unreliable especially in cases of elevated platelet turnover. Dual-color immunofluorescence staining and flowcytometry seems to be a much reliable method (25). Therefore, either the analysis

### Table 2. TPO Levels, PLT Count, Spleen Size and Index in Cirrhosis and Healthy Subjects a,b,c,d,e,f,g

|                  | Child A, (n = 3) | Child B, (n = 32) | Child C, (n = 30) | Liver Cirrhosis, Total, (n = 92) | Healthy Subjects, (n = 45) |
|------------------|-----------------|-------------------|------------------|---------------------------------|--------------------------|
| TPO, pg/mL       | 64 ± 11         | 75 ± 13           | 68 ± 10          | 69 ± 12                         | 49 ± 9                   |
| PLT count, mm3    | 134358 ± 9208   | 92416 ± 7607      | 58136 ± 5476     | 97000 ± 8000                    | 240000 ± 51000           |
| Spleen size, cm3  | 119 ± 14        | 144 ± 13          | 175 ± 11         | 148 ± 14                        | 98 ± 11                  |
| SVI, cm3          | 6616 ± 216      | 9363 ± 246        | 12529 ± 300      | 9167 ± 287                      | 4118 ± 123               |

a Data are presented as Mean ± SD.
b Abbreviation: SVI, Spleen volum index.
c Liver Cirrhosis (Total) versus healthy subjects P < 0.05
d Liver Cirrhosis (Total) versus healthy subjects P < 0.001.
e Child A vs. Child B P < 0.05 Child A vs. Child C P < 0.001 Child B vs. Child C P < 0.05.
f Liver Cirrhosis (Total) versus healthy subjects P < 0.001.
g Liver Cirrhosis (Total) versus healthy subjects P < 0.001.
of marrow megakaryocytes by conventional light microscopy method or assuming the marrow megakaryocyte density as normal in liver cirrhosis will not be reliable. In conclusion, cirrhotic thrombocytopenia is a multifactorial condition but our results suggest that accelerated platelet clearance in the periphery due to splenic sequestration seems to be the main factor for the thrombocytopenia in liver cirrhosis, rather than impaired thrombopoiesis due to TPO insufficiency. Points to clarify seems to be the factors enhancing splenic sequestration and impaired thrombopoiesis.

**Authors’ Contribution**

All authors contributed to this work equally.

**Funding/Support**

Financial support of the study was carried out by Eskisehir Ic Hastaliklari Derneği (Foundation of Eskisehir Internal Medicine).

**References**

1. Eckman R. The liver and hematopoiesis. In: Zakim D, Boyer TD editors. Hepatology. A Textbook of Liver Disease, third ed. Philadelphia: WB Saunders; 1996. pp. 685-90.
2. Hayashi H, Beppu T, Shirabe K, Maehara Y, Baba H. Management of thrombocytopenia due to liver cirrhosis: A review. World J Gastroenterol. 2014;20(10):2595–605.
3. Sanjo A, Satoh J, Ohnishi A, Maruno J, Fukata M, Suzuki N. Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. J Gastroenterol Hepatol. 2003;18(6):S84–4.
4. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood. 1995;86(2):419–31.
5. Shimada Y, Kato T, Ogami K, Horie T, Kubo K, Kudo Y, et al. Production of thrombopoietin (TPO) by rat hepatocytes and hematopoietic cell lines. Exp Hematol. 1995;23(1):3188–96.
6. Peck-Radosavljevic M, Zacherl J, Meng YG, Pidlich J, Lipinski E, Langle F, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? Journal of Hepatology. 1997;27(3):327–31.
7. Martin TJ, Somberg KA, Meng YG, Cohen RL, Heid CA, de Sauvage FJ, et al. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med. 1997;127(4):285–8.
8. Stiegler G, Stohlwetz P, Peck-Radosavljevic M, Jilma B, Pidlich J, Wichlas M, et al. Direct evidence for an increase in thrombopoietin after liver transplantation. Eur J Clin Invest. 1998;28(9):755–9.
9. Freni MA, Spadoro A, Ajello A, Barbaro E, Scaffidi M, Alessi N, et al. Serum thrombopoietin in chronic liver disease: relation to severity of the disease and spleen size. Hepatogastroenterology. 2002;49(47):1382–5.
10. Kawasaki T, Takeshita A, Souda K, Kobayashi Y, Kikuyama M, Suzuki F, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol. 1999;94(7):1918–22.
11. Koruk M, Onuk MD, Akcay F, Savas MC. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts. Hepatogastroenterology. 2002;49(48):3645–8.
12. Giannini E, Botta F, Borro P, Maffioli F, Fumagalli A, Testa E, et al. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. Am J Gastroenterol. 2003;98(5):2526–20.
13. Rios R, Sangro B, Herrero I, Quiroga J, Prieto J. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol. 2005;100(6):1311–6.
14. Espanol I, Gallego A, Enríquez J, Rabella N, Lerma E, Hernandez A, et al. Thrombocytopenia associated with liver cirrhosis and hepatitis C viral infection: role of thrombopoietin. Hepatogastroenterology. 2000;47(35):1404–6.
15. Ozer B, Serin E, Sezgin N, Cosar A, Guclu M, Gur G, et al. Thrombopoietin or interleukin-6 has no effect on thrombocytopenia of cirrhosis. Hepatogastroenterology. 2007;54(76):987–9.
16. Giannini E, Borro P, Botta F, Fumagalli A, Maffioli F, Podestà E, et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. Journal of Hepatology. 2002;37(5):572–7.
17. Schoffski P, Tacke F, Trautwein C, Martin MU, Casefritz M, Hecker H, et al. Thrombopoietin serum levels are elevated in patients with hepatitis B/C infection compared to other causes of chronic liver disease. Liver. 2002;22(1):8–20.
18. Akyuz F, Yekeler E, Kaymakoglu S, Horasanli S, Biritmen D, Demir K, et al. The role of thrombopoietin and spleen volume in thrombocytopenia of patients with noncirrhotic and cirrhotic portal hypertension. Turk J Gastroenterol. 2007;18(2):95–9.
19. Okubo M, Shiota G, Kawasaki H. Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. Clin Sci (Lond). 2000;99(3):207–14.
20. Aref S, Mabed M, Selim T, Goda T, Khafagy N. Thrombopoietin (TPO) levels in hepatic patients with thrombocytopenia. Hematology. 2004;9(5–6):351–6.
21. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(6):646–9.
22. Hallen A, Nilsson IM. Coagulation Studies in Liver Disease. Thr O Dia Thaumo. 1964;11:51–63.
23. Harker IA, Finch CA. Thrombokinetics in man. J Clin Invest. 1969;48(6):963–74.
24. Marongiu F, Mamusa AM, Manelli G, Mulas G, Cambuli AB, Piga M, et al. Thrombocytopenia and liver cirrhosis evidence for relationship between platelet count, spleen size and hepatic synthetic activity. Thrombosis Research. 1987;45(3):275–8.
25. Pradella P, Bonetto S, Turchetto S, Uxa L, Comar C, Zorat F, et al. Platelet production and destruction in liver cirrhosis. J Hepatol. 2012;54(5):894–903.
26. Kajihara M, Okazaki Y, Kato S, Ishii H, Kawakami Y, Ikeda Y, et al. Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol. 2007;22(1):312–8.
27. Shimodaira S, Ishida F, Ichikawa N, Tahara T, Kato T, Kodaira H, et al. Serum thrombopoietin (c-Mpl ligand) levels in patients with liver cirrhosis. Thr Haemost. 1996;26(4):545–8.
28. Berman L, Axelrod AR, et al. The blood and bone marrow in patients with cirrhosis of the liver. Blood. 1949;4(5):51–33.
29. Sheikh MY, Alaa PR, Riaz M, Oberer C, Moffett MJ. Prevalence of cirrhosis in patients with thrombocytopenia who receive bone marrow biopsy. Saudi J Gastroenterol. 2012;18(4):257–62.
30. Barsam SJ, Paaila B, Forestier M, Page IK, Sloane PA, Geyer JT, et al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood. 2013;117(21):5723–32.